April 11 Johnson & Johnson said on
Friday it was ending its efforts to bring to market a rival drug
to Allergan Inc's popular Botox anti-wrinkle treatment.
J&J had acquired the drug, PurTox, with its 2009 purchase of
Mentor, a leading maker of breast implants for cosmetic
augmentation and reconstructive surgery.
"After careful consideration, our Mentor business has
decided to discontinue its neurotoxin program, commonly known as
PurTox, in order to focus on its core breast surgery business,
where we are an established leader and see greater opportunities
to benefit patients and grow our business," J&J spokesman Thomas
Sanford said in an emailed statement.
Ending the PurTox development program will result in the
elimination of a small number of jobs in the United States, the
Botox is Allergan's biggest selling product with annual
sales of more than $2 billion and little serious competition.
The drug is primarily used cosmetically via injections to
erase wrinkles on the forehead. It has also been approved for
several medical uses such as to treat overactive bladder,
migraine headaches, upper limb spasticity and severe underarm
J&J declined to say whether it would take a charge
associated with halting the anti-wrinkle drug development. The
company is expected to report first quarter financial results
(Reporting by Bill Berkrot)